Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for children with autism spectrum disorder
ACTRN12617000441314Phase 4Completed
- Sponsor
- University of Sydney
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Intranasal oxytocin with Placebo nasal spray (2 arms). Primary endpoints: Social interaction skills and Clinical Global Impression - Improvement Scale. Started Apr 2017; status: completed.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12617000441314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000441314.